Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519847
rs1057519847
EGFR
0.030 GeneticVariation BEFREE EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. 26338423

2015
dbSNP: rs1057519848
rs1057519848
EGFR
0.030 GeneticVariation BEFREE EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. 26338423

2015
dbSNP: rs121434568
rs121434568
EGFR
0.030 GeneticVariation BEFREE EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. 26338423

2015
dbSNP: rs1057519847
rs1057519847
EGFR
0.030 GeneticVariation BEFREE Immunocytochemistry using two antibodies binding specifically to the major forms of mutant EGFR, L858R, and E746-A750 deletion (delE746-A750), was performed on cell blocks of malignant pleural effusion (MPE) from 78 patients with lung adenocarcinoma, who received first-line EGFR TKIs. 22525557

2012
dbSNP: rs1057519848
rs1057519848
EGFR
0.030 GeneticVariation BEFREE Immunocytochemistry using two antibodies binding specifically to the major forms of mutant EGFR, L858R, and E746-A750 deletion (delE746-A750), was performed on cell blocks of malignant pleural effusion (MPE) from 78 patients with lung adenocarcinoma, who received first-line EGFR TKIs. 22525557

2012
dbSNP: rs121434568
rs121434568
EGFR
0.030 GeneticVariation BEFREE Immunocytochemistry using two antibodies binding specifically to the major forms of mutant EGFR, L858R, and E746-A750 deletion (delE746-A750), was performed on cell blocks of malignant pleural effusion (MPE) from 78 patients with lung adenocarcinoma, who received first-line EGFR TKIs. 22525557

2012
dbSNP: rs1057519847
rs1057519847
EGFR
0.030 GeneticVariation BEFREE Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. 21444121

2011
dbSNP: rs1057519848
rs1057519848
EGFR
0.030 GeneticVariation BEFREE Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. 21444121

2011
dbSNP: rs121434568
rs121434568
EGFR
0.030 GeneticVariation BEFREE Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. 21444121

2011
dbSNP: rs113488022
rs113488022
BRAF
0.010 GeneticVariation BEFREE Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib. 27923714

2017
dbSNP: rs121913377
rs121913377
BRAF
0.010 GeneticVariation BEFREE Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib. 27923714

2017
dbSNP: rs397517132
rs397517132
EGFR
0.010 GeneticVariation BEFREE Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib. 27923714

2017